Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ:CRMD). The investigation concerns whether CorMedix and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On March 25, 2025, CorMedix issued a “business update” including net revenue guidance for the first half of 2025 of $50-$60 million (the “Guidance”) that fell below consensus analyst estimates. As CorMedix further revealed, the Guidance shortfall was driven by its “Large Dialysis Operator” customer, which had previously informed CorMedix of “operational resource constraints” that would delay its implementation of CorMedix’s DefenCath product. In response to this Guidance news, the price of CorMedix shares fell by $2.40 per share, from $11.09 per share on March 24, 2025, to close at $8.69 on March 2
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? [Yahoo! Finance]Yahoo! Finance
- CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswire
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
- Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 144
- 12/11/25 - Form 4
- CRMD's page on the SEC website